Meeting
2015 ASCO Annual Meeting
IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC.
Authors
Julien Mazières
Hôpital Larrey CHU Toulouse, Toulouse, France
Julien Mazières , Fabrice Barlesi , Oliver Molinier , Isabelle Monnet , Clarisse Audigier-Valette , Benjamin Besse , Anne Claire Toffart , Patrick-Aldo Renault , Philippe Masson , Bertrand Mennecier , Severine Moreau Fraboulet , Sandrine Hiret , Virginie Westeel , Patrick Dumont , Alexis B. Cortot , Eric Pichon , Marie Paule Lebitasy , Franck Morin , Gerard Zalcman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01556191
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS8110)
DOI
10.1200/jco.2015.33.15_suppl.tps8110
Abstract #
TPS8110
Poster Bd #
431a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
First Author: Julien Mazieres
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2018 ASCO Annual Meeting
Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.
First Author: Chul Kim
Poster
2014 ASCO Annual Meeting
Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).
First Author: Primo Lara Jr.